

ADEPT: feasibility of estimating the risk of adverse pregnancy, neonatal and child outcomes following either in utero ASM exposure through the mother, or periconceptional ASM exposure through the father

First published: 23/10/2024

Last updated: 13/03/2025

Study

Ongoing

Administrative details

PURI

<https://redirect.ema.europa.eu/resource/1000000246>

EU PAS number

EUPAS1000000246

Study ID

1000000246

DARWIN EU® study

No

Study countries

- ☐ Finland
 - ☐ France
 - ☐ Italy
 - ☐ Netherlands
 - ☐ Norway
 - ☐ Spain
 - ☐ United Kingdom
-

Study description

This study seeks to assess the feasibility of estimating the risk of adverse pregnancy, neonatal and child outcomes after periconceptional maternal or paternal exposure to antiseizure medications (ASM), or in-utero ASM exposure, using data from 9 electronic healthcare databases in Europe.

This main objective has the following sub-objectives:

- a. To estimate the availability of relevant information/characteristics for pregnant women, using the 15 different parameters that will inform the assessment of fitness for purpose.
- b. To estimate availability of relevant information/characteristics for men and linkage with pregnancies, using 9 different parameters that will inform the assessment of fitness for purpose.
- c. To estimate availability of relevant information/characteristics for neonates/children, using the following 17 parameters and comparing them between those that can and cannot be linked to mother and/or father where possible.
- d. To assess fitness for purpose to different types of studies of pre conceptional/prenatal exposure to antiepileptics and the development of

adverse pregnancy and child outcomes.

We will leverage data, human resources, expertise, methods, and infrastructures that are available in the EU PE&PV, ConcepTION, and VAC4EU networks. For this specific purpose, we included 9 pre-selected data sources from 7 countries whose data quality will be characterised using available INSIGHT tools (level 1-2 quality checks) that operate on the ConcepTION CDM structure. The source population comprises 48 million persons. This study will be conducted under the ENCePP code of conduct. The protocol, reports, code lists, clinical definition forms and phenotype algorithms, results and programs will be made publicly available with digital object identifiers in line with FAIR principles.

Study status

Ongoing

Research institutions and networks

Institutions

Division of Pharmacoepidemiology & Clinical Pharmacology (PECP), Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University

☐ Netherlands

First published: 01/03/2010

Last updated: 23/05/2024

Institution

Educational Institution

ENCePP partner

University Medical Center Utrecht (UMCU)

☐ Netherlands

First published: 24/11/2021

Last updated: 22/02/2024

Institution

Educational Institution

Hospital/Clinic/Other health care facility

ENCePP partner

Utrecht University

Toulouse University Hospital

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Finnish Institute for Health and Welfare (THL)

☐ Finland

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Educational Institution

Laboratory/Research/Testing facility

Health Services Research and Pharmacoepidemiology Unit (HSRP Unit) FISABIO

☐ Spain

First published: 30/11/2023

Last updated: 30/11/2023

Institution

Other

ENCePP partner

Clinical Pharmacology, Vall d'Hebron Institut de Recerca (VHIR)

☐ Spain

First published: 18/05/2021

Last updated: 20/05/2021

Institution

Hospital/Clinic/Other health care facility

ENCePP partner

Innovative Solutions for Medical Prediction And Big Data Integration In Real World Setting Srl (INSPIRE Srl), University Of Messina

☐ Italy

First published: 15/11/2021

Last updated: 15/11/2021

Institution

Educational Institution

ENCePP partner

The PHARMO Institute for Drug Outcomes Research (PHARMO Institute)

☐ Netherlands

First published: 07/01/2022

Last updated: 24/07/2024

Institution

Laboratory/Research/Testing facility

ENCePP partner

Pharmacology Unit - Veneto Pharmacovigilance Centre (Pharmacol UNIVR), University Hospital Verona

☐ Italy

First published: 25/10/2022

Last updated: 13/03/2025

Institution

Educational Institution

Hospital/Clinic/Other health care facility

ENCePP partner

Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina,

IDIAPJGol

☐ Spain

First published: 05/10/2012

Last updated: 23/02/2024

Institution

Educational Institution

Laboratory/Research/Testing facility

Not-for-profit

ENCePP partner

Agenzia regionale di sanità della Toscana (ARS)

☐ Italy

First published: 01/02/2024

Last updated: 12/03/2024

Institution

EU Institution/Body/Agency

ENCePP partner

University of Oslo

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Networks

EU Pharmacoepidemiology and Pharmacovigilance (PE&PV) Research Network

☐ Netherlands

First published: 01/02/2024

Last updated: 26/11/2024

Network

Contact details

Study institution contact

Clara Rodríguez

Study contact

clara.rodriguez@fisabio.es

Primary lead investigator

Miriam Sturkenboom

Primary lead investigator

ORCID number:

0000-0003-1360-2388

Study timelines

Date when funding contract was signed

Planned: 29/02/2024

Actual: 18/04/2024

Study start date

Planned: 18/11/2024

Actual: 18/11/2024

Data analysis start date

Planned: 02/05/2025

Date of final study report

Planned: 16/03/2026

Sources of funding

- EMA

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Feasibility analysis

Data collection methods:

Secondary use of data

Study design:

Study using four different retrospective cohorts.

Main study objective:

To assess the feasibility of estimating the risk of adverse pregnancy, neonatal and child outcomes after periconceptional maternal or paternal exposure to antiseizure medications (ASM), or in-utero ASM exposure, using data from 9 electronic healthcare databases in Europe.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Name of medicine, other

Methylphenobarbital, phenobarbital, primidone, barbexaclone, metharbital, ethotoin, phenytoin, amino(diphenylhydantoin) valeric acid, mephentyoin, fosphenytoin, paramethadione, trimethadione, ethadione, phensuximide, mesuximide, ethosuximide, combinations, clonazepam, carbamazepine, oxcarbazepine, rufinamide, valproic acid, valpromide, aminobutyric acid, vigabatrin, progabide, sultiame, phenacemide, lamotrigine, felbamate, topiramate, pheneturide, levetiracetam, zonisamide, stiripentol, lacosamide, carisbamate, retigabine, perampanel, brivaracetam, cenobamate, fenfluramine, ganaxolone, beclamide, gabapentin, pregabalin, mirogabalin.

Anatomical Therapeutic Chemical (ATC) code

(N02BF) Gabapentinoids

Gabapentinoids

(N03A) ANTIEPILEPTICS

ANTIEPILEPTICS

Population studied

Short description of the study population

The source population comprises the 9 included data sources, BIFAP (ES), SIDIAP (ES), VID (ES), CPRD (UK), Finish registries (FI), EFEMERIS (FR), Norwegian registries (NO), PHARMO (NL), and Val Padana LHU (IT) between 01/01/2000 and latest availability. We will assess many different parameters in different groups with the aim to generate indicators for the final fit-for-purpose assessment of different study questions using the Gatto framework (Gatto et al. 2022). For objectives a-c multiple cohorts (all population, mother, father, neonate/child) will be created which depend on the parameter that is being

assessed.

Age groups

Neonate

Infants and toddlers (28 days - 23 months)

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adult and elderly population (≥ 18 years)

Adults (18 to < 65 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Elderly (≥ 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Special population of interest

Pregnant women

Estimated number of subjects

40000000

Study design details

Setting

This study will be conducted using electronic health record data from 9 data sources in 7 countries in Europe comprising a total active population of 49 million persons. This includes BIFAP (ES), SIDIAP (ES), VID (ES), CPRD (UK), Finish registries (FI), EFEMERIS (FR), Norwegian registries (NO), PHARMO (NL),

and Val Padana LHU (IT). The source population comprises all individuals, men and women, of childbearing age and their offspring. Data sources vary in the type of data banks that can be accessed. Participation per sub-objective differs based on data availability for the specific objectives and the finite resources/timelines. Some Data Access Partners (DAPs) will re-use the data instance they use for ConcePTION (UiO, CHUT), whereas other DAPs re-extract and All countries (i.e., 7) and DAPS will participate in each sub-objective and more than 2 DAPs (i.e., 6 as UU, THL, CHUT, UiO, PHARMO, INSPIRE) have data completeness for 15 years.

Comparators

NA

Outcomes

Outcome parameters for Objective 2 are evaluated for each sub-objective using several pre-established parameters. Here are some examples:

Objective 2a: Feasibility Parameters for Women

- Percentage of pregnant individuals with complete ATC codes for each antiepileptic drug by data source, in the year before and during pregnancy. This inspects potential exposure misclassification and compares data sources.
- Proportion of adverse pregnancy outcomes, such as spontaneous pregnancy loss, induced abortion, stillbirth (>20-28 weeks), and preterm birth (<37 weeks' gestation). This inspects potential outcomes misclassification, benchmarks against national statistics, and compares data sources.

Objective 2b: Feasibility Parameters for Men and Paternal Linkage

- Percentage of men with complete ATC codes for each antiepileptic drug (ATC N03A) by data source, calendar year, and age group. This inspects potential exposure misclassification and compares data sources.
- Percentage of pregnancies identified using the ConcePTION algorithm with a

linked father, by linkage method (deterministic, probabilistic), data source, and calendar year. This inspects father-pregnancy linkage and compares data sources.

Objective 2c: Feasibility Parameters for Neonates/Children

- Duration of follow-up after birth among those registered from birth, including the percentage in follow-up at 1, 2, 3, 5, 11, and 15 years. This inspects the length of follow-up.

- Percentage of neonates with recorded major congenital malformations within 90 days, used for descriptive purposes and benchmarking across data sources and against EUROCAT.

- Risk of ADHD at 5, 11, and 15 years using different algorithms in those registered within 1 month after birth, used for descriptive purposes and benchmarking across data sources.

- Percentage of neonates with information on paternal exposure to antiepileptic drugs preconception, used to assess the prevalence of exposure.

Data analysis plan

Feasibility parameters:

For objective 2a-2c we will estimate the 41 feasibility parameters. Descriptive analyses will be used to report as well as graphics to show time trends and comparisons between data sources. Benchmark data will be obtained from the literature (e.g. WHO or EUROPERISTAT), to have an external validation on pregnancies and outcomes.

Feasibility to determine associations of pre conceptional/prenatal parental exposure to antiepileptics and the development of adverse pregnancy and child outcomes:

We will use the parameters from objectives 1-2 plus metadata on the data sources and assess the fitness-for-purpose of the data instance by using, implementing, and adapting the framework from Gatto N, and colleagues.

(Gatto et al., 2022). This is an assessment tool aimed at conducting feasibility assessment to determine whether a data source is fit-for-purpose for specific real-world effectiveness and safety study. Gatto's feasibility assessment framework is composed of three operative steps: i) operationalization and ranking of minimal criteria required to answer the research question; ii) identification and narrowing down data sources options, and iii) conducting detailed feasibility assessment. This third step will allow us to tabulate different evaluation items and therefore to score an overall assessment.

Documents

Study, other information

[Abstract_ADEPT_Protocol Obj.2_v1.pdf](#)(15.01 KB)

Data management

Data sources

Data source(s)

The Information System for Research in Primary Care (SIDIAP)

The Valencia Health System Integrated Database

Clinical Practice Research Datalink (CPRD) GOLD

EFEMERIS

Norwegian Health Registers

PHARMO Data Network

BIFAP - Base de Datos para la Investigación Farmacoepidemiológica en el Ámbito Público (Pharmacoepidemiological Research Database for Public Health Systems)

Data source(s), other

Val Padana LHU

Data sources (types)

[Administrative healthcare records \(e.g., claims\)](#)

[Disease registry](#)

[Drug registry](#)

[Drug utilisation data](#)

[Electronic healthcare records \(EHR\)](#)

[Population registry](#)

[Pregnancy registry](#)

Use of a Common Data Model (CDM)

CDM mapping

Yes

CDM Mappings

CDM name

ConcepTION CDM

CDM website

<https://www.imi-conception.eu/>

CDM release frequency

6 months

Data quality specifications

Check conformance

Yes

Check completeness

Yes

Check stability

Yes

Check logical consistency

Yes

Data characterisation

Data characterisation conducted

Yes

Data characterisation moment

after extract-transform-load to a common data model

after creation of study variables